TOP TEN perturbations for 1553183_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1553183_at
Selected probe(set): 1553183_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1553183_at (1553183_at) across 6672 perturbations tested by GENEVESTIGATOR:

ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) / ovarian tumor study 30 (PDX; mixed tumor, malignant, NOS; primary)

Relative Expression (log2-ratio):3.5555363
Number of Samples:2 / 2
Experimental ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary transitional cell carcinoma, NOS of the ovary (subcutaneously implanted).
Control ovarian tumor study 30 (PDX; mixed tumor, malignant, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary mixed tumor, malignant, NOS of the ovary (subcutaneously implanted).

ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) / ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary)

Relative Expression (log2-ratio):3.4798017
Number of Samples:2 / 2
Experimental ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary transitional cell carcinoma, NOS of the ovary (subcutaneously implanted).
Control ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenocarcinoma, NOS of the ovary (subcutaneously implanted).

ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) / ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary)

Relative Expression (log2-ratio):3.4416056
Number of Samples:2 / 2
Experimental ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary transitional cell carcinoma, NOS of the ovary (subcutaneously implanted).
Control ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary clear cell adenocarcinoma, NOS of the ovary (subcutaneously implanted).

ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) / ovarian tumor study 30 (PDX; serous cystadenocarcinoma, NOS; primary)

Relative Expression (log2-ratio):3.3017569
Number of Samples:2 / 13
Experimental ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary transitional cell carcinoma, NOS of the ovary (subcutaneously implanted).
Control ovarian tumor study 30 (PDX; serous cystadenocarcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary serous cystadenocarcinoma, NOS of the ovary (subcutaneously implanted).

precursor-B-ALL study 3 (PAX5-rearranged) / precursor-B-ALL study 3 (BCR-ABL)

Relative Expression (log2-ratio):2.7701578
Number of Samples:6 / 4
Experimental precursor-B-ALL study 3 (PAX5-rearranged)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [dic(9;20)(p11-13;q11) )/PAX5 rearranged]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).
Control precursor-B-ALL study 3 (BCR-ABL)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(9;22)(q34;q11.2)/BCR-ABL1]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).

AML study 1 (inv(16)/t(16;16)) / normal bone marrow sample

Relative Expression (log2-ratio):2.7492704
Number of Samples:28 / 74
Experimental AML study 1 (inv(16)/t(16;16))
Bone marrow samples of patients with acute myeloid leukemia (AML) with genetic aberration (inv(16)/t(16;16)).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

precursor-B-ALL study 3 (PAX5-rearranged) / precursor-B-ALL study 3 (hyperdiploid)

Relative Expression (log2-ratio):2.7403564
Number of Samples:6 / 17
Experimental precursor-B-ALL study 3 (PAX5-rearranged)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [dic(9;20)(p11-13;q11) )/PAX5 rearranged]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).
Control precursor-B-ALL study 3 (hyperdiploid)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL (hyperdiploidy). Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).

T-ALL study 1 / normal bone marrow sample

Relative Expression (log2-ratio):2.5287657
Number of Samples:174 / 74
Experimental T-ALL study 1
Bone marrow samples of patients with T-ALL.
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

precursor-B-ALL study 3 (PAX5-rearranged) / precursor-B-ALL study 3 (MLL-rearranged)

Relative Expression (log2-ratio):2.4134312
Number of Samples:6 / 5
Experimental precursor-B-ALL study 3 (PAX5-rearranged)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [dic(9;20)(p11-13;q11) )/PAX5 rearranged]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).
Control precursor-B-ALL study 3 (MLL-rearranged)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(v;11q23)/MLL rearranged]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).

zalypsis study 2 / untreated OPM1 cell sample

Relative Expression (log2-ratio):-2.336194
Number of Samples:2 / 2
Experimental zalypsis study 2
OPM1 multiple myeloma cells treated in vitro with zalypsis (5 nM), a novel marine-derived compound with potent antimyeloma activity. Cells were harvested at the beginning of induction of cell death (15-20% cell death as assessed by Annexin V-FITC staining). ATC code:---
Control untreated OPM1 cell sample
OPM1 multiple myeloma cells untreated.